203 related articles for article (PubMed ID: 36372016)
1. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.
Ghosh N; Couette N; van Binsbergen WH; Weinmann SC; Jivanelli B; Shea B; Bass AR; Benesova K; Bingham CO; Calabrese C; Cappelli LC; Chan KK; Choy E; Daoussis D; Goodman S; Hudson M; Jamal S; Leipe J; Lopez-Olivo MA; Suarez-Almazor M; van der Laken CJ; Meara AS; Liew D; Kostine M
Semin Arthritis Rheum; 2023 Feb; 58():152110. PubMed ID: 36372016
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
3. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
Tingry T; Massy E; Piperno M; Auroux M; Kostine M; Maillet D; Amini-Adle M; Fabien N; Estublier C; Goncalves D; Girard N; Confavreux CB
Bull Cancer; 2021 Jun; 108(6):643-653. PubMed ID: 33902919
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
5. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor-induced musculoskeletal manifestations.
Angelopoulou F; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
Rheumatol Int; 2021 Jan; 41(1):33-42. PubMed ID: 32743706
[TBL] [Abstract][Full Text] [Related]
7. Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group.
Helliwell T; Brouwer E; Pease CT; Hughes R; Hill CL; Neill LM; Halls S; Simon LS; Mallen CD; Boers M; Kirwan JR; Mackie SL
J Rheumatol; 2016 Jan; 43(1):182-6. PubMed ID: 26568595
[TBL] [Abstract][Full Text] [Related]
8. Rheumatic Complications of Immune Checkpoint Inhibitors.
Ghosh N; Bass AR
Rheum Dis Clin North Am; 2022 May; 48(2):411-428. PubMed ID: 35400368
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement.
Vermeulen OCB; Brouwer E; Slart RHJA; Sandovici M; Rutgers A; Hilterman TJ; Hiddinga B; Oosting SF; Jalving M; de Heij AH; Knapen DG; Hospers GAP; van der Geest KSM
Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38335930
[TBL] [Abstract][Full Text] [Related]
10. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
Abdel-Wahab N; Suarez-Almazor ME
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
[TBL] [Abstract][Full Text] [Related]
11. Polymyalgia Rheumatica: a Common Disease in Seniors.
Gazitt T; Zisman D; Gardner G
Curr Rheumatol Rep; 2020 Jun; 22(8):40. PubMed ID: 32562020
[TBL] [Abstract][Full Text] [Related]
12. The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica.
Mackie SL; Twohig H; Neill LM; Harrison E; Shea B; Black RJ; Kermani TA; Merkel PA; Mallen CD; Buttgereit F; Mukhtyar C; Simon LS; Hill CL;
J Rheumatol; 2017 Oct; 44(10):1515-1521. PubMed ID: 28765246
[TBL] [Abstract][Full Text] [Related]
13. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
Cappelli LC; Bingham CO
Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.
Singh N; Shahane A; Sparks JA; Bitoun S; Cappelli LC
Rheum Dis Clin North Am; 2024 May; 50(2):269-279. PubMed ID: 38670725
[TBL] [Abstract][Full Text] [Related]
15. Clinical Patterns and Follow-Up of Inflammatory Arthritis and Other Immune-Related Adverse Events Induced by Checkpoint Inhibitors. A Multicenter Study.
Gómez-Puerta JA; Lobo-Prat D; Perez-García C; Ponce A; Frade-Sosa B; Millán Arciniegas AM; Ojeda F; Ruiz-Esquide V; Corominas H
Front Med (Lausanne); 2022; 9():888377. PubMed ID: 35783644
[TBL] [Abstract][Full Text] [Related]
16. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA
Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850
[TBL] [Abstract][Full Text] [Related]
17. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
[TBL] [Abstract][Full Text] [Related]
18. PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial.
Marsman DE; Bolhuis TE; den Broeder N; den Broeder AA; van der Maas A
Trials; 2022 Apr; 23(1):318. PubMed ID: 35428320
[TBL] [Abstract][Full Text] [Related]
19. Imaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis.
Ponce A; Frade-Sosa B; Sarmiento-Monroy JC; Sapena N; Ramírez J; Azuaga AB; Morlà R; Ruiz-Esquide V; Cañete JD; Sanmartí R; Gómez-Puerta JA
Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010310
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management.
Williams SG; Mollaeian A; Katz JD; Gupta S
Expert Rev Clin Immunol; 2020 Aug; 16(8):771-785. PubMed ID: 32772596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
